Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer

Author： Koutsilieris Michael   Mitsiades Constantine S  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.10, Iss.6, 2001-06, pp. : 1099-1115

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Controversies of Androgen Ablation Therapy for Metastatic Prostate Cancer

By  

Current Pharmaceutical Design, Vol. 12, Iss. 7, 2006-03 ,pp. : 799-805

Bentham Science Publishers

Access to resources Recommend Favorite

Androgen deprivation therapy for prostate cancer

By Singer Eric A   Golijanin Dragan J   Miyamoto Hiroshi   Messing Edward M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 2, 2008-02 ,pp. : 211-228

Informa Healthcare

Access to resources Recommend Favorite

Concept and viability of androgen annihilation for advanced prostate cancer

By Mohler James L.  

Cancer, Vol. 120, Iss. 17, 2014-09 ,pp. : 2628-2637

Blackwell Publishing

Access to resources Recommend Favorite

Role of Androgen Ablation with Low-Dose-Rate Brachytherapy in the Treatment of Prostate Cancer

By Jani Ashesh B.   Shoushtari Asal   Feinstein Jeffrey M.  

Clinical Drug Investigation, Vol. 26, Iss. 12, 2006-01 ,pp. : 723-731

Adis International

Access to resources Recommend Favorite

The Effects of Dietary Factors on the Androgen Receptor and Related Cellular Factors in Prostate Cancer

By  

Current Medicinal Chemistry, Vol. 11, Iss. 7, 2004-04 ,pp. : 909-923

Bentham Science Publishers

Access to resources Recommend Favorite